32 results about "Peptide analog" patented technology

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.

The present invention relates to insect neuropeptide compounds of the family of pyroglutamic peptides and analogs thereof having activity against insects, such as Hemiptera, Diptera, Lepidoptera, Blattaria and / or Coleoptera insects, such as aphids and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1 / 2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.

The present disclosure discloses a composition of GLP-1 and PYY3-36 polypeptide analogues, a preparation method and use thereof, and relates to the technical field of biomedicines. The composition includes a GLP-1 polypeptide analogue and a PYY3-36 polypeptide analogue. Compared with the natural sequence of GLP-1 and the natural sequence of PYY3-36, the composition of the GLP-1 polypeptide analogue and the PYY3-36 polypeptide analogue has remarkable effects in ameliorating metabolic diseases such as obesity, diabetes mellitus, and fatty liver, and mood disorders such as anxiety and depression.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The present invention relates to compositions for use in the treatment of diabetes or obesity. In one embodiment, the present invention relates to a peptide analogue of pancreatic polypeptide (PP) for use in the treatment of diabetes or obesity. Also disclosed are methods of treatment of diabetes or obesity, and use of a peptide analogue according to the invention in the manufacture of a medicament for treating diabetes or obesity.

The present invention relates to a WKYMVm peptide analogue and uses thereof, and the WKYMVm peptide analogues have increased stability due to an increased in vivo degradation half-life, enhance activity of neutrophils as a formylpeptide receptor agonist, and regulate the activity of immune cells mediating pathology of multiple sclerosis so that they can be effectively used for enhancing immunity or preventing or treating multiple sclerosis.

Disclosed are peptide analogs derived from glucose dependent insulinotropic peptide (GIP), which are antagonists of the GIP receptor. These GIP peptide analogs are modified by comprising one or more individual amino acid substitutions and are conjugated to fatty acids with / without linkers, thereby having improved antagonistic activity and improved pharmacokinetic profiles.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

Hydrochloride salt forms of synthetic C-terminal peptide analogs of C5a, which are response selective agonists of C5aR-bearing antigen presenting cells. Methods of inducing an immune response in a subject by administering such peptide analogs alone or in combination with other active agents are also disclosed.

The application discloses a RAP polypeptide analogue and medical use thereof, and belongs to the polypeptide medical field, and the amino acid sequence of the RAP polypeptide analogue is Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17, and the N terminal of the RAP polypeptide analogue is acetylated, and the C terminal amino acid is amidated. Compared with the natural RAP polypeptide, the analogue has higher stability, bioavailability and drug efficacy, meanwhile, the dosage is low, the toxic and side effects are not obvious, the production cost is low, and the analogue has good popularization and clinical application prospects. The analogue is suitable for preventing and treating acute and chronic nephritis, chronic nephropathy and renal fibrosis caused by the acute and chronic nephritis, pulmonary inflammation and pulmonary fibrosis caused by the pulmonary inflammation, chronic liver disease and liver fibrosis caused by the chronic liver disease and the like.

The present invention relates to compounds comprising a modified W peptide analogue and optionally a conjugated moiety, and further optionally a linking group linking the modified W peptide and the conjugated moiety.

Provided are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds.

Disclosed are peptide analogs derived from glucose dependent insulinotropic peptide (GIP), which are antagonists of the GIP receptor. These GIP peptide analogs are modified by comprising one or more individual amino acid substitutions and are conjugated to fatty acids with / without linkers, thereby having improved antagonistic activity and improved pharmacokinetic profiles.

This article provides derivatives of sea hare proline-sea hare isoleucine peptide. It also provides peptide analogs, pharmaceutical compositions comprising these compounds, and methods for treating cancer with these compounds.

The invention belongs to the technical field of biology, and particularly relates to a human parathyroid hormone 1-34 peptide analogue and a preparation method and application of the human parathyroid hormone 1-34 peptide analogue, and the human parathyroid hormone 1-34 peptide analogue is formed by peptide fragments shown in SEQ ID No.1-SEQ ID No.8 or homologous peptide fragments of the peptide fragments. The human parathyroid hormone 1-34 peptide analogue has osteoporosis treatment activity, is used for relieving parathyroid hypofunction and related symptoms after parathyroid gland resection or extirpation, and also has an erection promoting function, and the preparation method is economical and environment-friendly, is suitable for industrial development and has a wide prospect.

This invention describes useful protein-drug conjugates and compositions thereof, for example, for targeting the glucagon-like peptide-1 receptor (GLP1R). In some embodiments, peptide analog payloads and linker-payloads are provided, as well as methods for preparing them. More specifically, GLP1 peptide analogs, antibody-drug conjugates, and compositions comprising an anti-GLP1R antibody and a GLP1 peptide analog payload are provided, as well as methods for treating GLP1R-related conditions.

Disclosed herein are methods of treating metabolic disorders, wherein the method administers a combination of a sodium / glucose co-transporter 1 (SGLT1) inhibitor and a glucagon-like peptide agonist 1 (GLP 1), a Gastrosuppressive Peptide-1 (GIP-1) analog, and / or d) a dual GLP-1-GIP-1 receptor agonist.

Disclosed are glucose-dependent insulinotropic peptide (GIP) derived peptide analogs that are antagonists of the GIP receptor. These GIP peptide analogs are modified by inclusion of the amino acid substitutions A13Aib and / or N24E and conjugated with a fatty acid with or without a linker, resulting in improved solubility and / or physical stability.

Anti-parasitic compounds and uses thereof. Compounds comprising a C-terminal peptide adjuvant conjugated to an N-terminal peptide antigen via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a, wherein said peptide antigen comprises an antigenic epitope of a parasitic organism, such as T. gondii. Methods of therapeutic or prophylactic treatment of a parasitic infections.

Provided herein are derivatives of an aplytic proline-aplytic isoleucine peptide. Also provided herein are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds.

Provided are a GLP-1 (7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.

The present invention relates to antimicrobial combinations for topical application. Particularly, it relates to antimicrobial combinations comprising an Indolicidin peptide analogue (C2), one or more non-ionic surfactants and at least an organic acid and / or metal salt thereof based chelating agent.

The present disclosure presents melanocortin receptor-specific peptides (e.g., novel α-MSH peptide analogs) which may be used in the treatment of melanocortin receptor-mediated diseases, indications, conditions, and syndromes.

Provided herein are peptide analogs of gastrin releasing peptide (GRP), corresponding pharmaceutical compositions, and methods of using such peptide analogs of GRP in the treatment of a disease or disorder, such as gastrointestinal disease or obesity.

To provide a radionuclide therapy which decays by emission of medium energy β - particles and emits γ - rays suitable for imaging purposes. Furthermore, the combination with appropriate targeting agents provides a coordinately acting radionuclide therapy.SOLUTION: A radiopeptide is provided comprising (a) a radionuclide that is terbium -161, (b) a chelating agent that coordinates terbium -161, and (c) a peptide or peptide analog that is a somatostatin receptor (SSTR) antagonist. The radioactive peptides are suitable for use in the treatment of tumor diseases.SELECTED DRAWING: None

The present invention relates to novel structures, synthesis methods, and applications of human somatostatin analogs comprising either a cyclic or non-cyclic hexapeptide unit, wherein the amino acid residues at positions 2 to 5 are represented by -X1-(D / L)-Trp-X2-X3-, or a cyclic or non-cyclic octapeptide unit, wherein the amino acid residues at positions 2 to 7 are represented by -Cys-X1-(D / L)-Trp-X2-X3-Cys-. In these sequences, X1 is an α-amino acid residue containing an aromatic group on the Cα side chain, X2 is a Lys derivative, and X3 is an α-amino acid residue. The Lys derivative has the following structure: wherein n is 0 or 1; A1, A2, and A3 are independently selected from C(R)2, O, S, NR, C=O, C=S, C=NR, and C=C(R)2. The present invention challenges the conventional understanding that modification of the Lys9 residue in somatostatin significantly reduces biological activity. By altering the Lys9 residue in somatostatin analogs, the present invention provides analogs with enhanced or comparable binding affinity to SSTR2, thereby improving their therapeutic efficacy.

The present invention relates to the pharmaceutical field, and specifically, to the following general formula (I): P-K-P-E-ψ-P-E-X 10 -D-X 12 -S-P-E-E-W-Q-R-Y-Y-X 22 -X 23 -L-R-H-Y-L-N-W-L-T-R-Q-R-Y-R1(I) A novel peptide tyrosine-tyrosine (PYY 3~36 ) analog or a salt or solvate thereof is provided, which contains the array structure as described above. The novel peptide YY analog (PYY 3~36 ) provided by the present invention has better pharmacological effects, longer action time, excellent bioavailability and safety.

The present disclosure relates to a polypeptide analog or a derivative thereof, and a preparation method and use thereof, and particularly to an agonistic polypeptide analog or a derivative thereof of an insulin amyloid polypeptide receptor. The polypeptide analog or the derivative thereof provided by the present disclosure has good agonistic activity on the insulin amyloid polypeptide receptor, has the characteristics of good stability, high activity, etc, at the same time, and can be used for treating and preventing diseases related to the insulin amyloid polypeptide receptor, such as body weight abnormality, especially obesity and overweight.